Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: A registry cohort analysis 1990-2005

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kaplan, Henry G ^a   Malmgren, Judith A ^b,c   Atwood, Mary K ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b HealthStat Consulting Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; TAXANE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MORTALITY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; RADIATION DOSE; RISK ASSESSMENT; BREAST TUMOR; INCIDENCE; KAPLAN MEIER METHOD; LEUKEMIA; MASTECTOMY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE COMPLICATION; RADIOTHERAPY; REGISTER; SECOND CANCER; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, RADIATION-INDUCED; MASTECTOMY; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY; REGISTRIES; TIME FACTORS; YOUNG ADULT;

EID: 79959212469     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-260     Document Type: Article

References (47)

1. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998, 9132:930-42. Early Breast Cancer Trialists' Collaborative Group.
2. NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer V.1.2010. 10/23/2009. 2009, National Comprehensive Care Network, Accessed February 11, 2010., http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
3. Curtis R, Boice J, Stovall M, Bernstein L, Greenburg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992, 326:1745-51. 10.1056/NEJM199206253262605, 1594016.
4. Diamandidou E, Buzdar A, Smith T, Frye D, Witjaksano M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 1996, 14:2722-2730.
5. Kaplan H, Malmgren J, Atwood M. Leukemia incidence following primary breast carcinoma treatment. Cancer 2004, 101(7):1529-1536. 10.1002/cncr.20475, 15378478.
6. Pederson-Bjergaard J, Philip P, Larsen SO, Jensen G, Brysting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990, 76(6):1083-91.
7. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995, 86(9):3542-3552.
8. Muss HB, Berry DB, Cirrincione C, Budman DR, Henderson IC, Ctron ML, Norton L, Winer EP, Hudis CA. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B Experience. J Clin Oncol 2007, 25:3699-704. 10.1200/JCO.2007.10.9710, 17704418.
9. Schaapveld M, Visser O, Louwman M, de Vries EGE, Willemse PHB, Otter R, van der Graaf WTA, Coebugh J-W W, van Leeuwen FE. Risk of new primary nonbreast cancers after breast cancer treatment: A Dutch population-based study. J Clin Oncol 2008, 26:1239-46. 10.1200/JCO.2007.11.9081, 18323547.
10. Padmanabhan A, Baker J, Zirpoli G, Sait SNJ, Ford LA, Moysich KB, Baer MR. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancer and of cancer in multiple family members. Leukemia Research 2008, 32:1820-23. 10.1016/j.leukres.2008.03.032, 18468682.
11. Crump M, Dongsheng T, Shepherd L, Levine M, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3066-71. 10.1200/JCO.2003.08.137, 12915595.
12. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbat P, Hey M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005, 23:4179-91. 10.1200/JCO.2005.05.029, 15961765.
13. Galper S, Gelman R, Recht A, Siver B, Kohli A, Wong JS, Van Buren T, Baldini EH, Harris JR. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiation Oncology Biol Phys 2002, 52(2):406-14.
14. Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Onc 2007, 25:292-300.
15. Hershman D, Neugut A, Jacobsen J, Wang J, Tsai W-Y, McBride R, Bennett CL, Grann VR. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007, 99:196-205. 10.1093/jnci/djk028, 17284714.
16. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2007, 25:3871-76. 10.1200/JCO.2007.12.0832, 17664457.
17. Van Leeuwen FE, Travis LB. Second Cancers. Cancer, Principles and Practice of Oncology 2001, 2939-2964. Philadelphia, PA: Lippincott Williams, and Wilkins, DeVita VT, Hellman S, Rosenberg SA, 6.
18. Neugut A, Weinberg MD, Ahsan H, Rescigno J. Carcinogenic effects of radiotherapy for breast cancer. Oncology 1999, 13(9):1245-1256.
19. Roychoudhuri R, Evans H, Robinson D, Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J of Cancer 2004, 91:868-872.
20. De Roos AJ, Deeg HJ, Davis S. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 2007, 18:1199-1208. 10.1007/s10552-007-9060-2, 17823848.
21. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003, 21:897-906. 10.1200/JCO.2003.07.113, 12610191.
22. Abrahamsen AF, Anderson A, Nome O, Abrahamsen JF, Kvaloy S. Long term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 2002, 13:1786-1791. 10.1093/annonc/mdf289, 12419752.
23. Delwail V, Jais JP, Colonna P, Andrieu J-M, . the GOELAMS (Groupe Ouest Est D'Etude Des Leucemies and Autres Maladies Du Sang Fifteen-year secondary leukaemia observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol 2002, 118:189-194. 10.1046/j.1365-2141.2002.03564.x, 12100147, the GOELAMS (Groupe Ouest Est D'Etude Des Leucemies and Autres Maladies Du Sang.
24. Surveillance, Epidemiology, and End Results (SEER) (2009) Program http://www.seer.cancer.gov SEER*stat Database: Incidence-SEER 9 Regs Limited-Use, Nov 2008 Sub (1973-2006) < Katrina/Rita Population Adjustment > - Linked to County Attributes - Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
25. American Joint Committee on Cancer Staging. 2002, New York, NY:Springer-Verlag, 6.
26. Fritz A, Percy C1, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S, . eds International classification of diseases for oncology. 2000, World Health Organization, Geneva, 3, eds.
27. http://seer.cancer.gov/siterecode/icdo3_d01272003
28. McCullagh P, Nelder JA. Generalized Linear Models. 1989, London: Chapman and Hall.
29. SPSS Version 17.0. 2009, Chicago: SPSS, Inc.
30. Efron B, Tibshirani RJ. An introduction to the bootstrap. 1993, Chapman and Hall, New York.
31. Rowley JD, Reshmi S, Sobulo O, Muvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, Behm F, Doggett NA, Borrow J, Zeleznik-Le N. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997, 90(2):535-541.
32. Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat 2009,
33. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF, . eds New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publ. No. 05-5302. Bethesda, MD, Curtis RE, Ron E, Hankey BF, Hoover RN, Chapter 7: New malignancies following breast cancer, eds., http://seer.cancer.gov/publications/mpmono/Ch07_Breast.pdf
34. Fisher B, Rockette H, Fisher ER, Wickerham DL, Redmond C, Brown A. Leukemia in breast cancer patients following adjuvant chemotherapy or post-operative radiation: the NSABP experience. J Clin Oncol 1985, 3:1640-1658.
35. Tallman M, Gray R, Bennett J, Variakojis D, Robert N, Wood W, Rowe JM, Wiernik PH. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Onc 1995, 13:1557-1563.
36. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 2003, 21:1195-1204. 10.1200/JCO.2003.03.114, 12663705.
37. Campone M, Roche H, Kerbat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquest P, Goudier M-J, Fumoleau P. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann of Onc 2005, 16:1343-1351.
38. Renella R, Verkooijen HM, Fioretta G, Vlastos G, Kurtz J, Sappino AP, Schafer P, Neyroud-Casper I, Bouchardy C. Increased risk of acute myeloid leukaemia after treatment for breast cancer. The Breast 2006, 15:614-619. 10.1016/j.breast.2005.11.007, 16386906.
39. Radivoyevitch T, Kozubek S, Sachs R K. Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions. Radiat Environ Biophys 2001, 40:1-9. 10.1007/s004110100088, 11357705.
40. Richardson DB, Wing S, Schroeder J, Schmitz-Feuerhake I, Hoffmann W. Ionizing Radiation and Chronic Lymphocytic Leukemia. Environ Health Perspec 2005, 113:1-5.
41. Tomonaga M, Matsuo T. A recent reclassification of leukemia cases among atomic bomb survivors demonstrates that the effects of radiation exposure differ depending on leukemia type. RERF Update 1991, 3(4):5-6.
42. Wakeford R. The cancer epidemiology of radiation. Oncogene 2004, 23(38):6404-6428. 10.1038/sj.onc.1207896, 15322514.
43. Malmgren JA, Atwood MK, Kaplan HG. Increase in mammography detected breast cancer over time at a community based regional cancer center: 1990-2005. BMC Cancer 2008, 8:131. 10.1186/1471-2407-8-131, 2405799, 18471303.
44. Shuryak I, Sachs RK, Brenner DJ. Cancer risks after radiation exposure in middle age. J Natl Cancer Inst 2010, 102:1628-1636. 10.1093/jnci/djq346, 20975037.
45. Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, Lowen MA, Ingle JN, Recht A, Wood WC. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Onc 2009, 27(32):5319-5324.
46. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009, 302(15):1685-92. 10.1001/jama.2009.1498, 19843904.
47. Zackrisson S, Nadersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 2006,